{
    "root": "2fc2580b-aae6-9960-e063-6394a90aacaf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Celecoxib",
    "value": "20250307",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "indications": "celecoxib capsules indicated",
    "contraindications": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) oa : 200 mg daily 100 mg twice daily . ( 2.2 , 14.1 ) rheumatoid arthritis : 100 mg 200 mg twice daily . ( 2.3 , 14.2 ) jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg . ( 2.4 , 14.3 ) : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit . ( 2.5 , 14.4 ) ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed . ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers . ( 2.7 , 8.8 , 12.3 ) .",
    "warningsAndPrecautions": "celecoxib capsules 200 mg available oral hard gelatin capsules white opaque body white opaque cap . “ apo c200 ” imprinted capsule yellow ink . supplied follows : bottles 10s ndc 43063-825-10 bottles 14s ndc 43063-825-14 bottles 30s ndc 43063-825-30 bottles 60s ndc 43063-825-60 storage : store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "celecoxib capsules contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . setting cabg surgery [ ( 5.1 ) ] . patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "indications_original": "Celecoxib capsules are indicated",
    "contraindications_original": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:\n                  Bottles of 10s                      NDC 43063-825-10\n                  Bottles of 14s                    NDC 43063-825-14\n                  Bottles of 30s                     NDC 43063-825-30\n                  Bottles of 60s                    NDC 43063-825-60\n                  \n                     Storage:Store at 20°C to 25°C (68°F\n \n   to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Celecoxib capsules are contraindicated in the following patients\n \n  :\n                  \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see\n  \n   Warnings and Precautions\n                        \n                           (5.7\n                           , 5.9)\n                        ].\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [\n  \n   see Warnings and Precautions (\n   \n    5.7\n                           , 5.8)\n                        ].\n \n  \n                     In the setting of CABG surgery [\n  \n   see\n   \n    Warnings and Precautions (5.1)\n                        ].\n \n  \n                     In patients who have demonstrated allergic-type reactions to sulfonamides\n  \n   [see Warnings and Precautions (\n   \n    5.7)]."
}